| Summary: | 碩士 === 長榮大學 === 醫學研究所 === 107 === Curcumin is the major component from Curcuma longa which has many pharmacological activities, such as antioxidant, anti-inflammatory, anti-bacteria and anti-cancer activity. Moreover structural modification of curcumin can be improved for its lower bioavailability. In this study, we evaluated curcuminoid derivative CM-F-A to treat CPs for 24-72 hours were observed in a dose-dependent using the MTT assay. The results showed that CM-F-A induced human colorectal cancer cell lines (CPs) cell cycle G2/M phase arrest. The activity of Cyclin B1/Cdk1 was present at G2/M transition. The results of western blot analysis have no inhibition of Cyclin B1. Moreover, CDK1 expression showed the significantly decreased. On the other hand, P-CDC25C showed the significantly increased, respectively. Therefore, CM-F-A could be applied as a leading compound for the development as an anti-colorectal cancer drug.
|
|---|
